Suppr超能文献

基于调强放疗的头颈部癌症再放疗的容积、剂量和分割考虑因素:多机构分析。

Volume, Dose, and Fractionation Considerations for IMRT-based Reirradiation in Head and Neck Cancer: A Multi-institution Analysis.

机构信息

Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.

Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.

出版信息

Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):606-617. doi: 10.1016/j.ijrobp.2017.11.036. Epub 2017 Dec 1.

Abstract

PURPOSE

Limited data exist to guide the treatment technique for reirradiation of recurrent or second primary squamous carcinoma of the head and neck. We performed a multi-institution retrospective cohort study to investigate the effect of the elective treatment volume, dose, and fractionation on outcomes and toxicity.

METHODS AND MATERIALS

Patients with recurrent or second primary squamous carcinoma originating in a previously irradiated field (≥40 Gy) who had undergone reirradiation with intensity modulated radiation therapy (IMRT); (≥40 Gy re-IMRT) were included. The effect of elective nodal treatment, dose, and fractionation on overall survival (OS), locoregional control, and acute and late toxicity were assessed. The Kaplan-Meier and Gray's competing risks methods were used for actuarial endpoints.

RESULTS

From 8 institutions, 505 patients were included in the present updated analysis. The elective neck was not treated in 56.4% of patients. The median dose of re-IMRT was 60 Gy (range 39.6-79.2). Hyperfractionation was used in 20.2%. Systemic therapy was integrated for 77.4% of patients. Elective nodal radiation therapy did not appear to decrease the risk of locoregional failure (LRF) or improve the OS rate. Doses of ≥66 Gy were associated with improvements in both LRF and OS in the definitive re-IMRT setting. However, dose did not obviously affect LRF or OS in the postoperative re-IMRT setting. Hyperfractionation was not associated with improved LRF or OS. The rate of acute grade ≥3 toxicity was 22.1% overall. On multivariable logistic regression, elective neck irradiation was associated with increased acute toxicity in the postoperative setting. The rate of overall late grade ≥3 toxicity was 16.7%, with patients treated postoperatively with hyperfractionation experiencing the highest rates.

CONCLUSIONS

Doses of ≥66 Gy might be associated with improved outcomes in high-performance patients undergoing definitive re-IMRT. Postoperatively, doses of 50 to 66 Gy appear adequate after removal of gross disease. Hyperfractionation and elective neck irradiation were not associated with an obvious benefit and might increase toxicity.

摘要

目的

针对复发性或第二原发头颈部鳞状细胞癌的再放疗,目前仅有少量数据可用于指导其治疗技术。我们进行了一项多机构回顾性队列研究,旨在调查选择性治疗体积、剂量和分割对结局和毒性的影响。

方法和材料

本研究纳入了在先前接受过放疗(≥40Gy)的区域内复发或第二原发鳞状细胞癌患者,这些患者接受了调强放疗(IMRT)再放疗(≥40Gy 再-IMRT)。评估了选择性淋巴结治疗、剂量和分割对总生存(OS)、局部区域控制以及急性和晚期毒性的影响。使用 Kaplan-Meier 和 Gray 竞争风险方法进行生存分析。

结果

在 8 家机构中,共有 505 例患者纳入本更新分析。56.4%的患者未行选择性颈部治疗。再-IMRT 的中位剂量为 60Gy(范围 39.6-79.2Gy)。20.2%的患者采用超分割放疗。77.4%的患者接受了综合系统治疗。选择性淋巴结放疗似乎并未降低局部区域失败(LRF)的风险或提高 OS 率。在根治性再-IMRT 治疗中,剂量≥66Gy 与 LRF 和 OS 的改善相关。然而,在术后再-IMRT 治疗中,剂量并未明显影响 LRF 或 OS。超分割放疗与 LRF 或 OS 的改善无关。总体急性 3 级以上毒性发生率为 22.1%。多变量逻辑回归分析显示,术后选择性颈部照射与急性毒性增加相关。总的晚期 3 级以上毒性发生率为 16.7%,接受术后超分割放疗的患者发生率最高。

结论

对于行根治性再-IMRT 的高绩效患者,剂量≥66Gy 可能与改善结局相关。术后,在大体疾病切除后,50 至 66Gy 的剂量似乎足够。超分割放疗和选择性颈部照射并未带来明显获益,反而可能增加毒性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18b6/7269162/edf8035a3459/nihms-1592015-f0001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验